Mylan N.V. (NASDAQ: MYL) is scheduled to release its first-quarter financial results before the markets open on Tuesday. The consensus forecast calls for $0.79 in earnings per share (EPS) and $2.7 billion in revenue. The same period of last year reportedly had EPS of $0.96 on $2.68 billion in revenue.
This past quarter, Mylan obtained approval to market its generic inhaler in three strengths. The Advair Diskus is marketed by GlaxoSmithKline PLC (NYSE: GSK), and this is far from being a small drug. Advair sales had been declining over time to about $3.1 billion globally in 2017, but the sales were over $5 billion in 2013. The website Statista showed that U.S. Advair sales were $1.6 billion in 2017.
Chronic lung diseases are serious issues for America and elsewhere. In the United States alone, over 26 million people are known to have asthma, and about 7 million of them are children. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that makes it hard to breathe and may become worse over time, and sadly there is no cure.
COPD can become debilitating and fatal over time. According to the American Lung Association, COPD is the third leading cause of death in the United States and more than 11 million people have been diagnosed with COPD. Sadly, the group warned that millions more may have the disease without even knowing it.
Excluding Monday’s move, Mylan had underperformed the broad markets, with its stock up about 2% year to date. In the past 52 weeks, the stock was actually up 24%.
A few analysts weighed in on Mylan ahead of the report:
- Cantor Fitzgerald has a Hold rating.
- Argus has a Buy rating with $32 price target
- SunTrust has a Buy rating and a $35 price target.
- UBS has a Neutral rating with a $31 price target.
- Credit Suisse has a Buy rating and a $37 target.
Shares of Mylan were last seen down less than 1% at $27.85, in a 52-week range of $26.00 to $42.50. The consensus price target is $35.94.